https://pubmed.ncbi.nlm.nih.gov/22282172/
Ann Intern Med
. 2012 Mar 20;156(6):463-5. doi: 10.7326/0003-4819-156-6-201203200-00386. Epub 2012 Jan 26.
Laboratory creation of a highly transmissible H5N1 influenza virus: balancing substantial risks and real benefits
Andrew T Pavia 1
PMID: 22282172 DOI: 10.7326/0003-4819-156-6-201203200-00386
Free article
Controversy erupted when influenza researchers announced that they had created an H5N1 influenza virus that was transmissible between ferrets. The controversy escalated when the National Science Advisory Board for Biosecurity (NSABB) recommended that the work be published but recommended significant voluntary redactions. The responses to the NSABB action and to the research itself have been polarized. A readily transmitted H5N1 virus could be extraordinarily lethal; therefore, the risk for accidental release is significant, and deliberate misuse of the data to create a biological weapon is possible. However, the knowledge gained by these and future experiments under appropriate safeguards is likely to allow critical understanding of influenza transmission and virulence. It would be irresponsible to adopt either extreme solution: to prevent and censor the research or to allow unlimited distribution without careful review by an independent group, such as the NSABB.
H5N1 - lab grown
Re: H5N1 - lab grown
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415850/
J Infect Dis. 2012 Jun 1; 205(11): 1628–1631.
Published online 2012 Mar 27. doi: 10.1093/infdis/jis257
PMCID: PMC3415850
PMID: 22454474
The Future of Research and Publication on Altered H5N1 Viruses
Sander Herfst, Albert D. M. E. Osterhaus, and Ron A. M. Fouchier
Abstract
Recently, we and others obtained experimental evidence that highly pathogenic avian influenza virus subtype H5 can acquire the ability to transmit via aerosols between ferrets. Upon submission of manuscripts describing the results of these studies, the US National Science Advisory Board for Biosecurity was consulted and recommended that the main conclusions of the work be published but without the experimental details and mutation data that would enable replication of the experiments. Over the past few months, these events have led to intense discussions. Should this type of experiment be conducted? If so, under what conditions? Do the scientific and public health benefits of the work and its publication outweigh the potential risks? In February 2012, public health and influenza experts discussed these issues during a World Health Organization–organized technical consultation. This perspective article reviews the current state of the field and the recommendations made during the meeting.
(See the perspectives by Bouveir, on pages 1632–5 and Osterholm and Relman, on pages 1636–8, and the editorial commentary by Hirsch, on pages 1621.)
https://doi.org/10.1093%2Finfdis%2Fjis259
Influenza A virus is a fascinating pathogen from a scientist's perspective, with a potentially high impact on animal and human health. The virus is enzootic in wild migratory birds of aquatic habitats around the world [1]. Influenza A viruses occasionally spill over from this avian “virus reservoir” into other animal hosts, including domestic poultry, pigs, horses, a variety of carnivores, and marine mammals. Most spillover events involve limited numbers of animals, but on occasion, when more sustained transmission within the new species takes place, they may result in large outbreaks. Sporadically, the viruses adapt to their new animal hosts, leading to enzootic virus circulation for years or decades [2].
Zoonotic influenza A virus infections also occur relatively frequently, often without serious consequences for public health [3]. However, the introduction of “novel” influenza viruses from animals into the human population can result in pandemics. One of the most devastating examples was the 1918 H1N1 “Spanish influenza” pandemic, which is estimated to have caused approximately 50 million deaths over a short period [4]. The later pandemics in 1957, 1968, and 2009 were mild compared with that of 1918, but they still caused excess morbidity and mortality involving up to several million human cases. After the pandemic period, the pandemic viruses become epidemic viruses and continue to cause substantial morbidity during seasonal epidemics, with, on average, 500 000 deaths globally each year [5].
Two major requirements determine the ability of a “new” influenza A virus strain to establish itself in the human population and cause a pandemic: (1) virus adaptation that enables efficient replication in the human respiratory tract and transmission between humans and (2) the absence of preexisting immunity in the human population. What exactly determines transmission of influenza viruses in humans has remained largely unknown, but all pandemic viruses studied to date have had the ability to be transmitted efficiently via aerosols or respiratory droplets (ie, airborne transmission) [6]. Only when we fully understand the viral and host factors that drive airborne transmission can we start to estimate the risk that influenza viruses in the animal world may pose for future influenza pandemics. Important information and insights can come from studies of pandemic and zoonotic viruses in the laboratory, using animal model systems and reverse genetics. One candidate virus for such studies is the highly pathogenic avian influenza (HPAI) A/H5N1 virus.
Since its first detection, in 1997, HPAI A/H5N1 virus has devastated the poultry industry of numerous countries of the Eastern Hemisphere. The continued circulation of A/H5N1 viruses in poultry for over a decade and their occasional spill over to wild birds and mammals, including humans, have led to ongoing virus evolution. More than 10 distinct “clades” of H5N1 viruses have been described since 1997, from which new sublineages or clades emerge periodically [7]. Whether such ongoing evolution could eventually lead to the emergence of A/H5N1 virus with pandemic potential has remained a key question since the first documented infections in humans, in Hong Kong. Many experts have judged this risk to be very low because of existing dogmas in the influenza field that stem from historical data on influenza pandemics: since all known previous pandemics were caused by influenza virus subtypes H1, H2, and H3 and since at least the last 2 emerged as a consequence of reassortment (ie, the mixing of genes of animal and human influenza viruses), it has often been argued that fully avian viruses of the H5 subtype could not gain pandemic potential [6]. Our research program aimed to test whether A/H5N1 virus could acquire the ability to spread via aerosols in mammals after undergoing genetic changes similar to those identified in previous pandemic viruses. The results of such work would help to better assess the risks of the current A/H5N1 epizootics for human health and would increase our understanding of the contribution of particular mutations or reassortments and their associated biological traits to transmission of the virus. In other words, this work may have major prognostic value for prediction, prevention, and treatment of the next pandemic.
Go to:
OVERSIGHT AND CONSULTATION
The work of Yoshihiro Kawaoka's team and our team followed the normal route in which research in the life sciences is performed. The research agenda within the influenza field was discussed with a broad range of experts at meetings coordinated by agencies such as the World Health Organization (WHO), the United Nations Food and Agriculture Organization (FAO), and the National Institute of Allergy and Infectious Diseases (NIAID) in the recent past. The need for more information on viral factors that affect transmission and contribute to the emergence of pandemic viruses was highlighted in the “Report of the Blue Ribbon Panel on Influenza Research, September 11–12, 2006” [8], the conclusions of the FAO–World Organization for Animal Health–WHO Joint Technical Consultation on avian influenza at the human-animal interface, held in Verona, Italy, during 7–9 October 2008 [9], and the “WHO Public Health Research Agenda for Influenza, 2009” [10]. Subsequently, funding agencies published requests for proposals to specifically address these issues [11, 12] or considered funding such work through open competitive grant programs. Proposals were then peer reviewed, and the most competitive proposals were funded. At that stage, the need to perform this particular line of research was clearly agreed upon by the research field as a whole, the scientists proposing the work, the funding agencies, and the external reviewers. From the conception phase of the research onward, biosafety and biosecurity experts were consulted to provide assurance that facilities and working conditions were such that the safety and security could be ensured at all times [13].
Go to:
BIOSAFETY
Work on HPAI A/H5N1 viruses has been carried out in many laboratories throughout the world since 1997. In most countries, such work is performed in enhanced biosafety level 3 (BSL3) facilities. A/H5N1 and other influenza viruses have not escaped from the laboratories in which such research has been performed. Although individual (unreported) laboratory-acquired infections may have occurred, this is in sharp contrast to the scenario discussed by Klotz and Sylvester [14], who concluded that 1% is the estimated probability of an escape from a single lab in a single year. This percentage was calculated on the basis of documented escapes of SARS coronavirus from laboratories that did not adhere to the BSL3 standards that are used in most countries. Research on class 3 pathogens, including transmissible HPAI A/H5N1 virus, can be done safely under enhanced BSL3 conditions by well-trained laboratory professionals, using strictly defined biosecurity and biosafety regulations to protect the researchers, the environment, and the public.
It is important to emphasize that even if individual occupational exposure to HPAI A/H5N1 virus occurred on rare occasion, primarily because of human error by personnel working under BSL3 and BSL4 conditions, several options are available to prevent subsequent exposure of the public at large and the environment. All of these options are in place at our facilities. First, H5 vaccines are offered to personnel handling the virus. Second, antiviral drugs are available for use as effective postexposure prophylaxis. Third, personnel can be quarantined upon exposure. Thus, despite the minute risk of occupational exposure, which is inherent to this type of work and perhaps unavoidable because of human error, the risks for the public and the environment can be reduced to nearly zero.
Go to:
HOW DANGEROUS WOULD AN AEROSOL-TRANSMISSIBLE H5N1 VIRUS BE FOR HUMANS?
Human cases of A/H5N1 virus infection are sporadic and occur predominantly upon direct exposure to infected birds and their products or to contaminated environments in areas where the virus is circulating in poultry. As of February 2012, 584 laboratory-confirmed cases of HPAI A/H5N1 virus infections in humans have been reported to the WHO, often with a clinically severe outcome and a high case-fatality rate of approximately 60%. Sustained human-to-human transmission of HPAI A/H5N1 virus has not yet been reported [15–17].
The case-fatality rate of 60% does not take into account potential mild or asymptomatic infections in people who are not seen by physicians or at hospitals. Serological studies in humans demonstrated that the incidence of H5N1 infection in exposed human populations is 1%–2% [18]. As a consequence, the case-fatality rate of A/H5N1 virus infection among humans may be significantly lower than the 60% deduced from laboratory-confirmed cases reported to the WHO.
Extrapolating from animal studies involving both macaques and ferrets, the virulence of the 1918 H1N1 virus, which had an estimated case-fatality rate of 2.5% in humans, was found to be within the same range as that for A/H5N1 virus [19]. Serious limitations of these animal studies are that virulence in animals and humans may be different, that virulence may vary with the route and dose of virus inoculation, and that virulence may be strain dependent. Overall, it is our opinion that data from human cases, serological analyses, and animal studies indicate that the case-fatality rate of 60% is a vast overestimate. Additional work to provide better estimates is urgently needed.
Go to:
SHOULD RESULTS OF THIS WORK BE PUBLISHED?
The likelihood of the airborne A/H5N1 virus being used by individuals or organizations with bad intentions is low. The possibility to do harm with this virus is probably low in terms of its transmission and virulence in humans, because it is unlikely that the virus would spread like a seasonal influenza virus in humans and because the case-fatality rate is likely much lower than currently estimated. The techniques that we used to create airborne A/H5N1 virus are not new and can be found in many virology textbooks. Individuals with bad intentions do not need to read the details in our manuscript because the methods for creating similar viruses have already been published widely. Moreover, the generation of such a virus requires well-trained experts and high-tech research techniques and facilities. In addition, there are many easier and cheaper ways for people with bad intentions to create a climate of fear by using infectious agents collected directly from nature.
Censoring the manuscripts on A/H5N1 virus transmission will, therefore, only create a false sense of security. Research aiming to unravel the genetic fingerprints associated with virus virulence, fitness, host range, and transmission needs to be done to enhance preparation for newly emerging infectious diseases. We agree with Peter Palese [20] that the more danger a pathogen poses, the more important it is to study it. As a consequence of our work, strong advice may be given to A/H5N1-affected countries about how to eradicate the virus from its animal reservoirs. Surveillance programs in countries where A/H5N1 is enzootic can now specifically target particular mutations that render A/H5N1 transmissible. In addition, we now have a relevant virus that can be used to test the efficacy of existing antivirals and to evaluate prepandemic vaccines. For the longer term, research of this and similar viruses will help us increase our fundamental understanding of why and how influenza viruses acquire the ability of aerosol transmission.
Go to:
THE WAY FORWARD
The fear that the transmissible A/H5N1 may escape from laboratories or may be intentionally released by people with bad intentions has resulted in a global public debate on the benefits and potential harm of this research. To provide time to better explain the benefits of this essential research and to explain the measures taken to minimize its possible risks, the influenza research community agreed to a voluntary pause of 60 days on any research resulting in A/H5N1 viruses that are more transmissible in mammals [21]. During the WHO-coordinated technical consultation in mid-February 2012 on H5N1 virus transmission research, unanimous support was given for this type of research, in the interest of science and public health. It was advised that the competent authorities should re-review biosafety and biosecurity conditions required to perform this work. At the same time, there should be focused communications to reduce anxiety among the public, increase awareness of the significance of this work, reassure that this type of work can be done safely and securely, and explain why the details of the work need to be published. It was further concluded that hiding key details from publications does not serve science or public health and that the confidential sharing of data classified as “dual use of concern” is impossible within a relevant time frame. As a consequence, the consensus view of the participants of this meeting was that full details of the studies should be published, in the interest of science and public health. After the expert judgments by the US National Science Advisory Board for Biosecurity and the WHO-assembled technical group, there is clearly also a need for broader consultation. We trust that in the interest of public health, the outcomes will be positive and constructive; that is, that the work will continue and that the manuscripts will be published responsibly, in the very near future.
Go to:
Notes
Financial support. The authors' work on A/H5N1 virus transmissions studies was financed by the National Institutes of Health/National Institute of Allergy and Infectious Diseases (contract HHSN266200700010C).
Potential conflicts of interest. A. D. M. E. O. is scientific advisor for 0.2 full-time equivalents to ViroClinics Biosciences. A. D. M. E. O. and R. A. M. F. are holders of certificates of shares in ViroClinics Biosciences B.V. To avoid any possible conflict of interests, Erasmus MC policy dictates that the shares as such are held by the Stichting Administratiekantoor Erasmus Personeelsparticipaties. The board of this foundation is appointed by the Board of Governors of the Erasmus MC and exercises all voting rights with regard to these shares.
All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Go to:
References
1. Olsen B, Munster VJ, Wallensten A, Waldenstrom J, Osterhaus AD, Fouchier RA. Global patterns of influenza a virus in wild birds. Science. 2006;312:384–8. [PubMed] [Google Scholar]
2. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol Rev. 1992;56:152–79. [PMC free article] [PubMed] [Google Scholar]
3. de Wit E, Kawaoka Y, de Jong MD, Fouchier RA. Pathogenicity of highly pathogenic avian influenza virus in mammals. Vaccine. 2008;26(Suppl 4):D54–8. [PMC free article] [PubMed] [Google Scholar]
4. Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918–1920 “Spanish” influenza pandemic. Bull Hist Med. 2002;76:105–15. [PubMed] [Google Scholar]
5. Stohr K. Influenza-WHO cares. Lancet Infect Dis. 2002;2:517. [PubMed] [Google Scholar]
6. Sorrell EM, Schrauwen EJA, Linster M, De Graaf M, Herfst S, Fouchier RAM. Predicting ‘airborne’ influenza viruses: (trans-) mission impossible? Current Opinion in Virology. 2011;1:635–42. [PMC free article] [PubMed] [Google Scholar]
7. WHO OIE FAO H5N1 Evolution Working Group. Continued evolution of highly pathogenic avian influenza A (H5N1): updated nomenclature. Influenza Other Respi Viruses. 2012;6:1–5. [PMC free article] [PubMed] [Google Scholar]
8. NIAID. Report of the blue ribbon panel on influenza research. Available at: http://www.niaid.nih.gov/topics/Flu/Doc ... influenzab lueribbonpanel2006.pdf. Accessed 3 April 2012. [Google Scholar]
9. FAO-OIE-WHO. Joint technical consultation on avian influenza at the human-animal interface. Available at: http://www.oie.int/fileadmin/Home/eng/C ... lusion.pdf. Accessed 3 April 2012. [PMC free article] [PubMed] [Google Scholar]
10. WHO. WHO public health research agenda for influenza, version 1, 2009. Available at: http://www.who.int/influenza/resources/resea rch/2010_04_29_global_influenza_research_agenda_version_01_en.pdf. Accessed 3 April 2012. [Google Scholar]
11. BAA NIH-NIAID-DMID-07-20. Available at: http://www.fbo.gov/index?s=opportunity& ... a&_cview=1. Accessed 3 April 2012. [Google Scholar]
12. FP7-HEALTH.2011.2.3.3-1. Available at: http://ec.europa.eu/research/participan ... -two-stage. Accessed 3 April 2012. [Google Scholar]
13. Fouchier RA, Herfst S, Osterhaus AD. Public health and biosecurity. Restricted data on influenza H5N1 virus transmission. Science. 2012;335:662–3. [PubMed] [Google Scholar]
14. Klotz L, Sylvester E. Preventing pandemics: the fight over flu. Nature. 2012;481:257–9. [PMC free article] [PubMed] [Google Scholar]
15. Kandun IN, Wibisono H, Sedyaningsih ER, et al. Three Indonesian clusters of H5N1 virus infection in 2005. N Engl J Med. 2006;355:2186–94. [PubMed] [Google Scholar]
16. Ungchusak K, Auewarakul P, Dowell SF, et al. Probable person-to-person transmission of avian influenza A (H5N1) N Engl J Med. 2005;352:333–40. [PubMed] [Google Scholar]
17. Wang H, Feng Z, Shu Y, et al. Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China. Lancet. 2008;371:1427–34. [PubMed] [Google Scholar]
18. Wang TT, Parides MK, Palese P. Seroevidence for H5N1 influenza infections in humans: meta-analysis. Science. 2012;335:1463. [PMC free article] [PubMed] [Google Scholar]
19. Kuiken T, van den Brand J, van Riel D, Pantin-Jackwood M, Swayne DE. Comparative pathology of select agent influenza a virus infections. Vet Pathol. 2010;47:893–914. [PubMed] [Google Scholar]
20. Palese P. Don't censor life-saving science. Nature. 2012;481:115. [PubMed] [Google Scholar]
21. Fouchier RA, Garcia-Sastre A, Kawaoka Y, et al. Pause on avian flu transmission research. Science. 2012;335:400–1. [PMC free article] [PubMed] [Google Scholar]
J Infect Dis. 2012 Jun 1; 205(11): 1628–1631.
Published online 2012 Mar 27. doi: 10.1093/infdis/jis257
PMCID: PMC3415850
PMID: 22454474
The Future of Research and Publication on Altered H5N1 Viruses
Sander Herfst, Albert D. M. E. Osterhaus, and Ron A. M. Fouchier
Abstract
Recently, we and others obtained experimental evidence that highly pathogenic avian influenza virus subtype H5 can acquire the ability to transmit via aerosols between ferrets. Upon submission of manuscripts describing the results of these studies, the US National Science Advisory Board for Biosecurity was consulted and recommended that the main conclusions of the work be published but without the experimental details and mutation data that would enable replication of the experiments. Over the past few months, these events have led to intense discussions. Should this type of experiment be conducted? If so, under what conditions? Do the scientific and public health benefits of the work and its publication outweigh the potential risks? In February 2012, public health and influenza experts discussed these issues during a World Health Organization–organized technical consultation. This perspective article reviews the current state of the field and the recommendations made during the meeting.
(See the perspectives by Bouveir, on pages 1632–5 and Osterholm and Relman, on pages 1636–8, and the editorial commentary by Hirsch, on pages 1621.)
https://doi.org/10.1093%2Finfdis%2Fjis259
Influenza A virus is a fascinating pathogen from a scientist's perspective, with a potentially high impact on animal and human health. The virus is enzootic in wild migratory birds of aquatic habitats around the world [1]. Influenza A viruses occasionally spill over from this avian “virus reservoir” into other animal hosts, including domestic poultry, pigs, horses, a variety of carnivores, and marine mammals. Most spillover events involve limited numbers of animals, but on occasion, when more sustained transmission within the new species takes place, they may result in large outbreaks. Sporadically, the viruses adapt to their new animal hosts, leading to enzootic virus circulation for years or decades [2].
Zoonotic influenza A virus infections also occur relatively frequently, often without serious consequences for public health [3]. However, the introduction of “novel” influenza viruses from animals into the human population can result in pandemics. One of the most devastating examples was the 1918 H1N1 “Spanish influenza” pandemic, which is estimated to have caused approximately 50 million deaths over a short period [4]. The later pandemics in 1957, 1968, and 2009 were mild compared with that of 1918, but they still caused excess morbidity and mortality involving up to several million human cases. After the pandemic period, the pandemic viruses become epidemic viruses and continue to cause substantial morbidity during seasonal epidemics, with, on average, 500 000 deaths globally each year [5].
Two major requirements determine the ability of a “new” influenza A virus strain to establish itself in the human population and cause a pandemic: (1) virus adaptation that enables efficient replication in the human respiratory tract and transmission between humans and (2) the absence of preexisting immunity in the human population. What exactly determines transmission of influenza viruses in humans has remained largely unknown, but all pandemic viruses studied to date have had the ability to be transmitted efficiently via aerosols or respiratory droplets (ie, airborne transmission) [6]. Only when we fully understand the viral and host factors that drive airborne transmission can we start to estimate the risk that influenza viruses in the animal world may pose for future influenza pandemics. Important information and insights can come from studies of pandemic and zoonotic viruses in the laboratory, using animal model systems and reverse genetics. One candidate virus for such studies is the highly pathogenic avian influenza (HPAI) A/H5N1 virus.
Since its first detection, in 1997, HPAI A/H5N1 virus has devastated the poultry industry of numerous countries of the Eastern Hemisphere. The continued circulation of A/H5N1 viruses in poultry for over a decade and their occasional spill over to wild birds and mammals, including humans, have led to ongoing virus evolution. More than 10 distinct “clades” of H5N1 viruses have been described since 1997, from which new sublineages or clades emerge periodically [7]. Whether such ongoing evolution could eventually lead to the emergence of A/H5N1 virus with pandemic potential has remained a key question since the first documented infections in humans, in Hong Kong. Many experts have judged this risk to be very low because of existing dogmas in the influenza field that stem from historical data on influenza pandemics: since all known previous pandemics were caused by influenza virus subtypes H1, H2, and H3 and since at least the last 2 emerged as a consequence of reassortment (ie, the mixing of genes of animal and human influenza viruses), it has often been argued that fully avian viruses of the H5 subtype could not gain pandemic potential [6]. Our research program aimed to test whether A/H5N1 virus could acquire the ability to spread via aerosols in mammals after undergoing genetic changes similar to those identified in previous pandemic viruses. The results of such work would help to better assess the risks of the current A/H5N1 epizootics for human health and would increase our understanding of the contribution of particular mutations or reassortments and their associated biological traits to transmission of the virus. In other words, this work may have major prognostic value for prediction, prevention, and treatment of the next pandemic.
Go to:
OVERSIGHT AND CONSULTATION
The work of Yoshihiro Kawaoka's team and our team followed the normal route in which research in the life sciences is performed. The research agenda within the influenza field was discussed with a broad range of experts at meetings coordinated by agencies such as the World Health Organization (WHO), the United Nations Food and Agriculture Organization (FAO), and the National Institute of Allergy and Infectious Diseases (NIAID) in the recent past. The need for more information on viral factors that affect transmission and contribute to the emergence of pandemic viruses was highlighted in the “Report of the Blue Ribbon Panel on Influenza Research, September 11–12, 2006” [8], the conclusions of the FAO–World Organization for Animal Health–WHO Joint Technical Consultation on avian influenza at the human-animal interface, held in Verona, Italy, during 7–9 October 2008 [9], and the “WHO Public Health Research Agenda for Influenza, 2009” [10]. Subsequently, funding agencies published requests for proposals to specifically address these issues [11, 12] or considered funding such work through open competitive grant programs. Proposals were then peer reviewed, and the most competitive proposals were funded. At that stage, the need to perform this particular line of research was clearly agreed upon by the research field as a whole, the scientists proposing the work, the funding agencies, and the external reviewers. From the conception phase of the research onward, biosafety and biosecurity experts were consulted to provide assurance that facilities and working conditions were such that the safety and security could be ensured at all times [13].
Go to:
BIOSAFETY
Work on HPAI A/H5N1 viruses has been carried out in many laboratories throughout the world since 1997. In most countries, such work is performed in enhanced biosafety level 3 (BSL3) facilities. A/H5N1 and other influenza viruses have not escaped from the laboratories in which such research has been performed. Although individual (unreported) laboratory-acquired infections may have occurred, this is in sharp contrast to the scenario discussed by Klotz and Sylvester [14], who concluded that 1% is the estimated probability of an escape from a single lab in a single year. This percentage was calculated on the basis of documented escapes of SARS coronavirus from laboratories that did not adhere to the BSL3 standards that are used in most countries. Research on class 3 pathogens, including transmissible HPAI A/H5N1 virus, can be done safely under enhanced BSL3 conditions by well-trained laboratory professionals, using strictly defined biosecurity and biosafety regulations to protect the researchers, the environment, and the public.
It is important to emphasize that even if individual occupational exposure to HPAI A/H5N1 virus occurred on rare occasion, primarily because of human error by personnel working under BSL3 and BSL4 conditions, several options are available to prevent subsequent exposure of the public at large and the environment. All of these options are in place at our facilities. First, H5 vaccines are offered to personnel handling the virus. Second, antiviral drugs are available for use as effective postexposure prophylaxis. Third, personnel can be quarantined upon exposure. Thus, despite the minute risk of occupational exposure, which is inherent to this type of work and perhaps unavoidable because of human error, the risks for the public and the environment can be reduced to nearly zero.
Go to:
HOW DANGEROUS WOULD AN AEROSOL-TRANSMISSIBLE H5N1 VIRUS BE FOR HUMANS?
Human cases of A/H5N1 virus infection are sporadic and occur predominantly upon direct exposure to infected birds and their products or to contaminated environments in areas where the virus is circulating in poultry. As of February 2012, 584 laboratory-confirmed cases of HPAI A/H5N1 virus infections in humans have been reported to the WHO, often with a clinically severe outcome and a high case-fatality rate of approximately 60%. Sustained human-to-human transmission of HPAI A/H5N1 virus has not yet been reported [15–17].
The case-fatality rate of 60% does not take into account potential mild or asymptomatic infections in people who are not seen by physicians or at hospitals. Serological studies in humans demonstrated that the incidence of H5N1 infection in exposed human populations is 1%–2% [18]. As a consequence, the case-fatality rate of A/H5N1 virus infection among humans may be significantly lower than the 60% deduced from laboratory-confirmed cases reported to the WHO.
Extrapolating from animal studies involving both macaques and ferrets, the virulence of the 1918 H1N1 virus, which had an estimated case-fatality rate of 2.5% in humans, was found to be within the same range as that for A/H5N1 virus [19]. Serious limitations of these animal studies are that virulence in animals and humans may be different, that virulence may vary with the route and dose of virus inoculation, and that virulence may be strain dependent. Overall, it is our opinion that data from human cases, serological analyses, and animal studies indicate that the case-fatality rate of 60% is a vast overestimate. Additional work to provide better estimates is urgently needed.
Go to:
SHOULD RESULTS OF THIS WORK BE PUBLISHED?
The likelihood of the airborne A/H5N1 virus being used by individuals or organizations with bad intentions is low. The possibility to do harm with this virus is probably low in terms of its transmission and virulence in humans, because it is unlikely that the virus would spread like a seasonal influenza virus in humans and because the case-fatality rate is likely much lower than currently estimated. The techniques that we used to create airborne A/H5N1 virus are not new and can be found in many virology textbooks. Individuals with bad intentions do not need to read the details in our manuscript because the methods for creating similar viruses have already been published widely. Moreover, the generation of such a virus requires well-trained experts and high-tech research techniques and facilities. In addition, there are many easier and cheaper ways for people with bad intentions to create a climate of fear by using infectious agents collected directly from nature.
Censoring the manuscripts on A/H5N1 virus transmission will, therefore, only create a false sense of security. Research aiming to unravel the genetic fingerprints associated with virus virulence, fitness, host range, and transmission needs to be done to enhance preparation for newly emerging infectious diseases. We agree with Peter Palese [20] that the more danger a pathogen poses, the more important it is to study it. As a consequence of our work, strong advice may be given to A/H5N1-affected countries about how to eradicate the virus from its animal reservoirs. Surveillance programs in countries where A/H5N1 is enzootic can now specifically target particular mutations that render A/H5N1 transmissible. In addition, we now have a relevant virus that can be used to test the efficacy of existing antivirals and to evaluate prepandemic vaccines. For the longer term, research of this and similar viruses will help us increase our fundamental understanding of why and how influenza viruses acquire the ability of aerosol transmission.
Go to:
THE WAY FORWARD
The fear that the transmissible A/H5N1 may escape from laboratories or may be intentionally released by people with bad intentions has resulted in a global public debate on the benefits and potential harm of this research. To provide time to better explain the benefits of this essential research and to explain the measures taken to minimize its possible risks, the influenza research community agreed to a voluntary pause of 60 days on any research resulting in A/H5N1 viruses that are more transmissible in mammals [21]. During the WHO-coordinated technical consultation in mid-February 2012 on H5N1 virus transmission research, unanimous support was given for this type of research, in the interest of science and public health. It was advised that the competent authorities should re-review biosafety and biosecurity conditions required to perform this work. At the same time, there should be focused communications to reduce anxiety among the public, increase awareness of the significance of this work, reassure that this type of work can be done safely and securely, and explain why the details of the work need to be published. It was further concluded that hiding key details from publications does not serve science or public health and that the confidential sharing of data classified as “dual use of concern” is impossible within a relevant time frame. As a consequence, the consensus view of the participants of this meeting was that full details of the studies should be published, in the interest of science and public health. After the expert judgments by the US National Science Advisory Board for Biosecurity and the WHO-assembled technical group, there is clearly also a need for broader consultation. We trust that in the interest of public health, the outcomes will be positive and constructive; that is, that the work will continue and that the manuscripts will be published responsibly, in the very near future.
Go to:
Notes
Financial support. The authors' work on A/H5N1 virus transmissions studies was financed by the National Institutes of Health/National Institute of Allergy and Infectious Diseases (contract HHSN266200700010C).
Potential conflicts of interest. A. D. M. E. O. is scientific advisor for 0.2 full-time equivalents to ViroClinics Biosciences. A. D. M. E. O. and R. A. M. F. are holders of certificates of shares in ViroClinics Biosciences B.V. To avoid any possible conflict of interests, Erasmus MC policy dictates that the shares as such are held by the Stichting Administratiekantoor Erasmus Personeelsparticipaties. The board of this foundation is appointed by the Board of Governors of the Erasmus MC and exercises all voting rights with regard to these shares.
All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Go to:
References
1. Olsen B, Munster VJ, Wallensten A, Waldenstrom J, Osterhaus AD, Fouchier RA. Global patterns of influenza a virus in wild birds. Science. 2006;312:384–8. [PubMed] [Google Scholar]
2. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol Rev. 1992;56:152–79. [PMC free article] [PubMed] [Google Scholar]
3. de Wit E, Kawaoka Y, de Jong MD, Fouchier RA. Pathogenicity of highly pathogenic avian influenza virus in mammals. Vaccine. 2008;26(Suppl 4):D54–8. [PMC free article] [PubMed] [Google Scholar]
4. Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918–1920 “Spanish” influenza pandemic. Bull Hist Med. 2002;76:105–15. [PubMed] [Google Scholar]
5. Stohr K. Influenza-WHO cares. Lancet Infect Dis. 2002;2:517. [PubMed] [Google Scholar]
6. Sorrell EM, Schrauwen EJA, Linster M, De Graaf M, Herfst S, Fouchier RAM. Predicting ‘airborne’ influenza viruses: (trans-) mission impossible? Current Opinion in Virology. 2011;1:635–42. [PMC free article] [PubMed] [Google Scholar]
7. WHO OIE FAO H5N1 Evolution Working Group. Continued evolution of highly pathogenic avian influenza A (H5N1): updated nomenclature. Influenza Other Respi Viruses. 2012;6:1–5. [PMC free article] [PubMed] [Google Scholar]
8. NIAID. Report of the blue ribbon panel on influenza research. Available at: http://www.niaid.nih.gov/topics/Flu/Doc ... influenzab lueribbonpanel2006.pdf. Accessed 3 April 2012. [Google Scholar]
9. FAO-OIE-WHO. Joint technical consultation on avian influenza at the human-animal interface. Available at: http://www.oie.int/fileadmin/Home/eng/C ... lusion.pdf. Accessed 3 April 2012. [PMC free article] [PubMed] [Google Scholar]
10. WHO. WHO public health research agenda for influenza, version 1, 2009. Available at: http://www.who.int/influenza/resources/resea rch/2010_04_29_global_influenza_research_agenda_version_01_en.pdf. Accessed 3 April 2012. [Google Scholar]
11. BAA NIH-NIAID-DMID-07-20. Available at: http://www.fbo.gov/index?s=opportunity& ... a&_cview=1. Accessed 3 April 2012. [Google Scholar]
12. FP7-HEALTH.2011.2.3.3-1. Available at: http://ec.europa.eu/research/participan ... -two-stage. Accessed 3 April 2012. [Google Scholar]
13. Fouchier RA, Herfst S, Osterhaus AD. Public health and biosecurity. Restricted data on influenza H5N1 virus transmission. Science. 2012;335:662–3. [PubMed] [Google Scholar]
14. Klotz L, Sylvester E. Preventing pandemics: the fight over flu. Nature. 2012;481:257–9. [PMC free article] [PubMed] [Google Scholar]
15. Kandun IN, Wibisono H, Sedyaningsih ER, et al. Three Indonesian clusters of H5N1 virus infection in 2005. N Engl J Med. 2006;355:2186–94. [PubMed] [Google Scholar]
16. Ungchusak K, Auewarakul P, Dowell SF, et al. Probable person-to-person transmission of avian influenza A (H5N1) N Engl J Med. 2005;352:333–40. [PubMed] [Google Scholar]
17. Wang H, Feng Z, Shu Y, et al. Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China. Lancet. 2008;371:1427–34. [PubMed] [Google Scholar]
18. Wang TT, Parides MK, Palese P. Seroevidence for H5N1 influenza infections in humans: meta-analysis. Science. 2012;335:1463. [PMC free article] [PubMed] [Google Scholar]
19. Kuiken T, van den Brand J, van Riel D, Pantin-Jackwood M, Swayne DE. Comparative pathology of select agent influenza a virus infections. Vet Pathol. 2010;47:893–914. [PubMed] [Google Scholar]
20. Palese P. Don't censor life-saving science. Nature. 2012;481:115. [PubMed] [Google Scholar]
21. Fouchier RA, Garcia-Sastre A, Kawaoka Y, et al. Pause on avian flu transmission research. Science. 2012;335:400–1. [PMC free article] [PubMed] [Google Scholar]
Re: H5N1 - lab grown
https://www.scientificamerican.com/arti ... -bred-flu/
DECEMBER 20, 2011
7 MIN READ
Fears Grow over Lab-Bred Avian Flu Virus
Scientists call for stricter biosafety measures for dangerous avian-influenza variants.
By Declan Butler of Nature magazine
It is a nightmare scenario: a human pandemic caused by the accidental release of a man-made form of the lethal avian influenza virus H5N1.
Yet the risk is all too real. Since September, news has been circulating about two groups of scientists who have reportedly created mutant H5N1 variants that can be transmitted between ferrets merely breathing the same air, generally an indicator that the virus could also spread easily among humans.
The work raises the specter of a disease that spreads as fast as ordinary seasonal flu, but with a fatality rate akin to wild-type H5N1--an order of magnitude greater than the mortality rate of roughly 2.5 percent seen during the catastrophic flu pandemic of 1918.
Until now, debate about the new variants has focused on whether the research poses too great a security risk to be published--even if partially redacted--a question currently under consideration by the U.S. National Science Advisory Board for Biosecurity (NSABB).
A number of scientists argue, however, that the NSABB's deliberations have come far too late. Because further research on the new variants now seems inevitable, a far more important question, they say, is whether the labs that hold samples of the virus--and those who will seek to work with them in the future--have sufficient biosafety protection to make sure it cannot escape.
"This horse is out of the barn," says Richard Ebright, a molecular biologist and biodefense expert at Rutgers University in Piscataway, N.J. "At this point, it is utterly futile to be discussing restricting the publication of this information," he adds, pointing out that the results have already been seen by many flu scientists, including referees, and are probably spreading through the flu grapevine faster than a speeding neutrino.
Sources say that one of the studies, led by Ron Fouchier of Erasmus Medical Center in Rotterdam, the Netherlands, has been submitted to Science, and that the other, led by Yoshihiro Kawaoka of the University of Wisconsin, Madison, has been sent to Nature. (Nature's journalists do not have access to submitted manuscripts or the journal's confidential deliberations on them.) Fouchier also presented his results in September at the annual European Scientific Working Group on Influenza conference in Malta. (Scientific American is part of Nature Publishing Group.)
The mutant strains were not born out of a reckless desire to push the boundaries of high-risk science, but to gain a better understanding of the potential for avian H5N1 to mutate into a form that can spread easily in humans through coughing or sneezing.
Some virologists have suggested that any genetic changes that made it more transmissible would probably blunt its deadliness. The new work seems to contradict that comforting idea. The studies should also help boost surveillance for similar changes in wild-type strains, and to develop diagnostics, drugs and vaccines.
Both experiments were conducted in labs rated at "biosafety level 3 (BSL-3) enhanced" (see "Safety by degrees"). Such labs require scientists to shower and change clothes when leaving the lab, and include other safety features such as negative air pressure and passing exhaust air through high-efficiency particulate air filters. This should be quite sufficient to provide protection against an accidental release of the virus, some virologists say.
"Current biosafety rules are adequate for safely doing such transmission experiments with H5N1 viruses or any other influenza virus," says Peter Palese, a virologist at Mount Sinai School of Medicine in New York.
Requiring the more stringent protocols of BSL-4 facilities would hamper the research needed to develop countermeasures against an H5N1 pandemic, says Masato Tashiro, a virologist at the National Institute of Infectious Diseases in Tokyo, because it would limit the number of researchers able to work with the virus. As such, he believes that the work should be done in BSL-3 enhanced facilities.
High security
But others say that to protect not only the researchers working on the viruses, but also society at large, the new H5N1 variants must be restricted to BSL-4 labs. These labs have far tougher safety and security measures, such as requiring workers to wear positive air pressure suits and undergo more rigorous decontamination; some also have additional security measures, such as video surveillance and bomb-proofing. Corralling this research in BSL-4 facilities would also immediately limit the proliferation of the viruses in labs, because only a few dozen such facilities exist worldwide, says Ebright. Indeed, one regulatory official, who requested anonymity, says that he is most concerned about the H5N1 mutants being handled in BSL-3 labs in countries with weak biosafety cultures or competences.
Deborah Middleton, an H5N1 researcher at the high-containment facilities at the Australian Animal Health Laboratory in Geelong, says that the characteristics of the new variants "fulfil the criteria of a BSL-4 pathogen," adding that she believes they would probably be handled as such in her institution. Indeed, the original experiments to create the viruses should also have been conducted in a BSL-4 facility, argues Hervé Raoul, director of the Jean Meriéux-INSERM BSL-4 lab in Lyons, France.
Past experience suggests that the risk of the new variant H5N1 escaping from a lab is far from negligible. Over the past decade, severe acute respiratory syndrome (SARS) has accidentally infected staff at four high-containment labs in mainland China, Taiwan and Singapore, variously rated as BSL-3 and BSL-4. A U.S. National Research Council report released in September detailed 395 biosafety breaches during work with select agents in the United States between 2003 and 2009--including seven laboratory-acquired infections--that risked accidental release of dangerous pathogens from high-containment labs.
And the rapid spread of an escaped flu virus would make it more dangerous than other deadly pathogens. "When SARS or BSL-4 agents get out, their potential for transmission on a global basis is quite limited," says Michael Osterholm, who heads the University of Minnesota's Center for Infectious Disease Research and Policy in Minneapolis, and is a member of the NSABB. "Influenza presents a very difficult challenge because if it ever were to escape, it is one that would quickly go round the world."
Fouchier declined to comment on these biosafety issues, saying only that his experiments had been reviewed by authorities in the Netherlands and the United States where "H5N1 virus is a class-3 agent because anti¬virals and vaccines are available". Kawaoka did not respond to interview requests.
Some scientists say that they are looking to the World Health Organization (WHO) to provide timely leadership in this biosafety debate. But Gregory Hartl, a spokesman for the WHO in Geneva, Switzerland, says the agency is unable to comment, because it has not yet seen the written studies. Meanwhile, the NSABB has not said when it will publish its advice. In a statement to Nature, the U.S. Department of Agriculture said that it (and the U.S. Department of Health and Human Services) will conduct any appropriate technical review of the new H5N1 variants.
Ebright laments that important questions of biosafety and biosecurity are largely left to the discretion of individual researchers. "In the United States, there is only voluntary oversight for biosafety, and with the exception of the select agents rule, there is no oversight of bio¬security," he says. Given the choice, says Middleton, flu researchers often resist working in higher biocontainment levels simply because they would no longer have the convenience of doing their research in BSL-3 labs at their own institutes, and because working in a BSL-4 lab is inherently more difficult.
The situation contrasts sharply with the barrage of legislation to regulate research that involves placing human subjects at risk, notes Ebright, where proposed projects are rigorously reviewed before they can start. "What's remarkable," says Ebright, is that for dual-use research of this type on H5N1, "which puts at risk not one individual but potentially hundreds, thousands or millions of individuals, there is no oversight whatsoever."
On December 20, the U.S. National Science Advisory Board for Biosecurity (NSABB) released a statement outlining its recommendations to the authors of the two flu studies under review, and to the editors of the journals that are considering publishing them. The statement says:
"Due to the importance of the findings to the public health and research communities, the NSABB recommended that the general conclusions highlighting the novel outcome be published, but that the manuscripts not include the methodological and other details that could enable replication of the experiments by those who would seek to do harm. The NSABB also recommended that language be added to the manuscripts to explain better the goals and potential public health benefits of the research, and to detail the extensive safety and security measures taken to protect laboratory workers and the public."
In response, Science's Editor-in-Chief Bruce Alberts said:
"Science editors will be evaluating how best to proceed. Our response will be heavily dependent upon the further steps taken by the U.S. government to set forth a written, transparent plan to ensure that any information that is omitted from the publication will be provided to all those responsible scientists who request it, as part of their legitimate efforts to improve public health and safety."
In response, Nature's Editor-in-Chief Philip Campbell said:
"We have noted the unprecedented NSABB recommendations that would restrict public access to data and methods and recognize the motivation behind them. It is essential for public health that the full details of any scientific analysis of flu viruses be available to researchers. We are discussing with interested parties how, within the scenario recommended by NSABB, appropriate access to the scientific methods and data could be enabled."
DECEMBER 20, 2011
7 MIN READ
Fears Grow over Lab-Bred Avian Flu Virus
Scientists call for stricter biosafety measures for dangerous avian-influenza variants.
By Declan Butler of Nature magazine
It is a nightmare scenario: a human pandemic caused by the accidental release of a man-made form of the lethal avian influenza virus H5N1.
Yet the risk is all too real. Since September, news has been circulating about two groups of scientists who have reportedly created mutant H5N1 variants that can be transmitted between ferrets merely breathing the same air, generally an indicator that the virus could also spread easily among humans.
The work raises the specter of a disease that spreads as fast as ordinary seasonal flu, but with a fatality rate akin to wild-type H5N1--an order of magnitude greater than the mortality rate of roughly 2.5 percent seen during the catastrophic flu pandemic of 1918.
Until now, debate about the new variants has focused on whether the research poses too great a security risk to be published--even if partially redacted--a question currently under consideration by the U.S. National Science Advisory Board for Biosecurity (NSABB).
A number of scientists argue, however, that the NSABB's deliberations have come far too late. Because further research on the new variants now seems inevitable, a far more important question, they say, is whether the labs that hold samples of the virus--and those who will seek to work with them in the future--have sufficient biosafety protection to make sure it cannot escape.
"This horse is out of the barn," says Richard Ebright, a molecular biologist and biodefense expert at Rutgers University in Piscataway, N.J. "At this point, it is utterly futile to be discussing restricting the publication of this information," he adds, pointing out that the results have already been seen by many flu scientists, including referees, and are probably spreading through the flu grapevine faster than a speeding neutrino.
Sources say that one of the studies, led by Ron Fouchier of Erasmus Medical Center in Rotterdam, the Netherlands, has been submitted to Science, and that the other, led by Yoshihiro Kawaoka of the University of Wisconsin, Madison, has been sent to Nature. (Nature's journalists do not have access to submitted manuscripts or the journal's confidential deliberations on them.) Fouchier also presented his results in September at the annual European Scientific Working Group on Influenza conference in Malta. (Scientific American is part of Nature Publishing Group.)
The mutant strains were not born out of a reckless desire to push the boundaries of high-risk science, but to gain a better understanding of the potential for avian H5N1 to mutate into a form that can spread easily in humans through coughing or sneezing.
Some virologists have suggested that any genetic changes that made it more transmissible would probably blunt its deadliness. The new work seems to contradict that comforting idea. The studies should also help boost surveillance for similar changes in wild-type strains, and to develop diagnostics, drugs and vaccines.
Both experiments were conducted in labs rated at "biosafety level 3 (BSL-3) enhanced" (see "Safety by degrees"). Such labs require scientists to shower and change clothes when leaving the lab, and include other safety features such as negative air pressure and passing exhaust air through high-efficiency particulate air filters. This should be quite sufficient to provide protection against an accidental release of the virus, some virologists say.
"Current biosafety rules are adequate for safely doing such transmission experiments with H5N1 viruses or any other influenza virus," says Peter Palese, a virologist at Mount Sinai School of Medicine in New York.
Requiring the more stringent protocols of BSL-4 facilities would hamper the research needed to develop countermeasures against an H5N1 pandemic, says Masato Tashiro, a virologist at the National Institute of Infectious Diseases in Tokyo, because it would limit the number of researchers able to work with the virus. As such, he believes that the work should be done in BSL-3 enhanced facilities.
High security
But others say that to protect not only the researchers working on the viruses, but also society at large, the new H5N1 variants must be restricted to BSL-4 labs. These labs have far tougher safety and security measures, such as requiring workers to wear positive air pressure suits and undergo more rigorous decontamination; some also have additional security measures, such as video surveillance and bomb-proofing. Corralling this research in BSL-4 facilities would also immediately limit the proliferation of the viruses in labs, because only a few dozen such facilities exist worldwide, says Ebright. Indeed, one regulatory official, who requested anonymity, says that he is most concerned about the H5N1 mutants being handled in BSL-3 labs in countries with weak biosafety cultures or competences.
Deborah Middleton, an H5N1 researcher at the high-containment facilities at the Australian Animal Health Laboratory in Geelong, says that the characteristics of the new variants "fulfil the criteria of a BSL-4 pathogen," adding that she believes they would probably be handled as such in her institution. Indeed, the original experiments to create the viruses should also have been conducted in a BSL-4 facility, argues Hervé Raoul, director of the Jean Meriéux-INSERM BSL-4 lab in Lyons, France.
Past experience suggests that the risk of the new variant H5N1 escaping from a lab is far from negligible. Over the past decade, severe acute respiratory syndrome (SARS) has accidentally infected staff at four high-containment labs in mainland China, Taiwan and Singapore, variously rated as BSL-3 and BSL-4. A U.S. National Research Council report released in September detailed 395 biosafety breaches during work with select agents in the United States between 2003 and 2009--including seven laboratory-acquired infections--that risked accidental release of dangerous pathogens from high-containment labs.
And the rapid spread of an escaped flu virus would make it more dangerous than other deadly pathogens. "When SARS or BSL-4 agents get out, their potential for transmission on a global basis is quite limited," says Michael Osterholm, who heads the University of Minnesota's Center for Infectious Disease Research and Policy in Minneapolis, and is a member of the NSABB. "Influenza presents a very difficult challenge because if it ever were to escape, it is one that would quickly go round the world."
Fouchier declined to comment on these biosafety issues, saying only that his experiments had been reviewed by authorities in the Netherlands and the United States where "H5N1 virus is a class-3 agent because anti¬virals and vaccines are available". Kawaoka did not respond to interview requests.
Some scientists say that they are looking to the World Health Organization (WHO) to provide timely leadership in this biosafety debate. But Gregory Hartl, a spokesman for the WHO in Geneva, Switzerland, says the agency is unable to comment, because it has not yet seen the written studies. Meanwhile, the NSABB has not said when it will publish its advice. In a statement to Nature, the U.S. Department of Agriculture said that it (and the U.S. Department of Health and Human Services) will conduct any appropriate technical review of the new H5N1 variants.
Ebright laments that important questions of biosafety and biosecurity are largely left to the discretion of individual researchers. "In the United States, there is only voluntary oversight for biosafety, and with the exception of the select agents rule, there is no oversight of bio¬security," he says. Given the choice, says Middleton, flu researchers often resist working in higher biocontainment levels simply because they would no longer have the convenience of doing their research in BSL-3 labs at their own institutes, and because working in a BSL-4 lab is inherently more difficult.
The situation contrasts sharply with the barrage of legislation to regulate research that involves placing human subjects at risk, notes Ebright, where proposed projects are rigorously reviewed before they can start. "What's remarkable," says Ebright, is that for dual-use research of this type on H5N1, "which puts at risk not one individual but potentially hundreds, thousands or millions of individuals, there is no oversight whatsoever."
On December 20, the U.S. National Science Advisory Board for Biosecurity (NSABB) released a statement outlining its recommendations to the authors of the two flu studies under review, and to the editors of the journals that are considering publishing them. The statement says:
"Due to the importance of the findings to the public health and research communities, the NSABB recommended that the general conclusions highlighting the novel outcome be published, but that the manuscripts not include the methodological and other details that could enable replication of the experiments by those who would seek to do harm. The NSABB also recommended that language be added to the manuscripts to explain better the goals and potential public health benefits of the research, and to detail the extensive safety and security measures taken to protect laboratory workers and the public."
In response, Science's Editor-in-Chief Bruce Alberts said:
"Science editors will be evaluating how best to proceed. Our response will be heavily dependent upon the further steps taken by the U.S. government to set forth a written, transparent plan to ensure that any information that is omitted from the publication will be provided to all those responsible scientists who request it, as part of their legitimate efforts to improve public health and safety."
In response, Nature's Editor-in-Chief Philip Campbell said:
"We have noted the unprecedented NSABB recommendations that would restrict public access to data and methods and recognize the motivation behind them. It is essential for public health that the full details of any scientific analysis of flu viruses be available to researchers. We are discussing with interested parties how, within the scenario recommended by NSABB, appropriate access to the scientific methods and data could be enabled."